- Home
- SLGB vs PRLD Comparison
SLGB vs PRLD Comparison
Compare SLGB & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | PRLD |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3M | 207.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLGB | PRLD |
|---|---|---|
| Price | $0.97 | $3.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 92.5K | ★ 315.5K |
| Earning Date | 03-31-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $0.92 | $0.61 |
| 52 Week High | $6.02 | $4.19 |
Technical Indicators
Market Signals| Indicator | SLGB | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 56.89 |
| Support Level | $0.92 | $1.02 |
| Resistance Level | $1.48 | $4.10 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.92 | 50.68 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.